Infigratinib not checked

QED Therapeutics, a BridgeBio company · BGJ398

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2/3 trial completes
Trials
4 active
7 in total · 4 in the EU
Targets
 

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
How it’s given
“* The dose of infigratinib will be the dose confirmed in the Phase 2 portion and used in the Phase 2b portion for the age group. * The dose and number of sprinkle capsules/day will be calculated based on individual participant age and weight. Doses will be adjusted based on age and weight changes approximately every 3 months for the first year and every 6 months thereafter.”In the company’s words, NCT07169279 on ClinicalTrials.gov
Tested for
Hypochondroplasia (2 trials), Achondroplasia (2 trials)
Main trialPhase 2/3
“ACCEL2/3 is a Phase 2/3 study. The purpose of the Phase 2 portion of the study (ACCEL2/3) is to evaluate the efficacy and safety of infigratinib in children with hypochondroplasia (HCH) receiving infigratinib at one of two doses, who have completed at least 26 weeks of participation in QED-sponsored ACCEL (QBGJ398-004).”In the company’s words, NCT06873035 on ClinicalTrials.gov
Other names
BGJ398

Other drugs for Hypochondroplasia

All 3 drugs for Hypochondroplasia

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials7

TrialPhaseCompletesWhat it tests
Phase 2/3Enrolling by invitation Jan 2027 An Interventional Study of Infigratinib in Children With Hypochondroplasia
Phase 2Recruiting Mar 2030 Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
Phase 2Enrolling by invitation 1 Dec 2031 Extension Study of Infigratinib in Children With Achondroplasia (ACH)
Phase 2Enrolling by invitation 31 May 2036 Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
Phase 3Terminated 2 Mar 2023 Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
Phase 2Terminated 1 Mar 2021 A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
Phase 2Completed 10 Jan 2023 LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Infigratinib

Following is part of Solo: you see every change to Infigratinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in